Phase I, Open-Label, Multi-Center, Dose Escalation With Expansion Trial of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy in Relapse/Refractory Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies

Trial Profile

Phase I, Open-Label, Multi-Center, Dose Escalation With Expansion Trial of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy in Relapse/Refractory Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs MVT 1075 (Primary) ; MVT 5873
  • Indications Colon cancer; Lung cancer; Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Sponsors MabVax Therapeutics
  • Most Recent Events

    • 17 Oct 2017 According to a MabVax Therapeutics media release, the company anticipates to report interim data from the study near the end of the year.
    • 11 Oct 2017 According to a MabVax Therapeutics media release, announced the initiation of patient enrollment at a second site Memorial Sloan Kettering Cancer Center.
    • 27 Jun 2017 According to a MabVax Therapeutics media release, first patient has been dosed in this study and company expects to report interim trial results by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top